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Abstract 27 
 28 
The purpose of this review article is to examine the evidence of the mechanisms 29 
linking obesity with bowel cancer risk and to comment on the development of 30 
interventions which that may lower risk of this common age-related disease. The 31 
choice of topics for inclusion reflect my personal research on the aetiology and 32 
prevention of bowel cancer over the past 3 decades. I have cited literature which 33 
addresses each of these topics but, because of the breadth of the review article, I 34 
have not attempted to do this systematically. The accumulation of genomic damage 35 
which leads to colorectal (bowel) cancer (CRC) is influenced by the balance between 36 
damage acquisition through environmental exposures and endogenous factors/ 37 
processes and the effectiveness of genomic repair mechanisms. There is now 38 
convincing evidence that obesity is associated with increased bowel cancer risk and 39 
this increased risk is apparent even among those with Lynch Syndrome who are 40 
genetically predisposed to the disease. It seems likely that genomic damage 41 
resulting from obesity-related inflammation is a key driver of colorectal tumorigenesis 42 
but mechanisms may also include altered insulin/ IGF1 signalling which may give 43 
tumour cells a competitive advantage. The importance of inflammation as a mediator 44 
of the effects of obesity is supported by the fall in CRC risk which follows sustained 45 
exposure to NSAID such as aspirin and the abrogation of the excess CRC risk in 46 
obese patients with Lynch Syndrome who were randomised to aspirin.  Since the 47 
available evidence about the effects of weight loss in the obese on CRC risk is 48 
limited, this should be a high priority for future research. In the meantime, to lower 49 
the global CRC burden, it would be prudent to institute effective public measures to 50 
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reduce the development of obesity and to enable those who are obese to lose 51 
weight.  52 
 53 
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1. Introduction: Aetiology of colorectal (bowel) cancer – role of environmental 57 
exposures and endogenous factors 58 
 59 
All cancers are due to genomic damage in stem cells which causes silencing of 60 
tumour suppressor genes and/ or activation of oncogenes. The accumulation of 61 
genomic damage is influenced by the balance between damage acquisition through 62 
environmental exposures and endogenous factors/ processes and the effectiveness 63 
of genomic repair mechanisms. The latter is influenced by both genotype (which 64 
establishes the capacity for repair) and the environment (which influences the 65 
expression/ activity of repair-related proteins). Because of the important role of 66 
lifestyle factors and other environmental exposures in influencing cancer risk, it has 67 
been estimated that, globally, 30 – 50% of all cancers are preventable [1]. Colorectal 68 
cancer (CRC) risk increases with age and with exposure to risk factors including, 69 
importantly, lifestyle factors. CRC is one of the most preventable cancers and it has 70 
been estimated that 54% of bowel cancer cases in the UK are potentially 71 
preventable [2]. 72 
 73 
Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch 74 
Syndrome, is a cancer predisposition syndrome that results in early onset CRC as 75 
well as cancers at other sites including the endometrium, stomach, and upper urinary 76 
tract.  Lynch Syndrome is inherited in an autosomal dominant fashion, is caused by 77 
germ-line mutation in one of the genes encoding the DNA mismatch repair system 78 
and is characterised by a type of genomic instability known as microsatellite 79 
instability. MLH1 is one of the commonest genes mutated in Lynch Syndrome and, in 80 
addition, this gene is silenced epigenetically by hypermethylation of the promoter 81 
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region in about one sixth of sporadic CRC [3]. For these reasons, Lynch Syndrome is 82 
an informative model for investigating effects of dietary and other factors in the 83 
aetiology and prevention of bowel cancer as discussed below. 84 
 85 
1.1 Purpose of, and processes used in, this review article 86 
This narrative review is based on an invited presentation at the conference marking 87 
the 50th Anniversary of Korean Nutrition Society. The topics for inclusion reflect my 88 
personal research on the aetiology and prevention of bowel cancer over the past 3 89 
decades. I have cited literature which addresses each of these topics but, because 90 
of the breadth of the review article, I have not attempted to do this systematically. 91 
 92 
2. Obesity and bowel cancer risk 93 
 94 
There is strong evidence that obesity increases CRC risk. A systematic review and 95 
meta-analysis of 56 observational studies involving more than 7 million individuals 96 
and 93,812 CRC cases, confirmed that higher BMI was associated with increased 97 
bowel cancer risk in both prospective and retrospective studies [4]. In this analysis, 98 
for every 5 units (kg.m-2) increase in BMI, CRC risk increased by 18%. This 99 
association with adiposity was stronger for colon than for rectal cancer and for men 100 
than for women [4]. In addition, increased adiposity is a significant risk factor for 101 
colorectal adenomas [5] which are premalignant precursors of bowel tumours. This 102 
suggests that increased body fatness may act at an early stage in colorectal 103 
tumorigenesis. In particular, there is a linear dose-response relationship between 104 
abdominal fatness (visceral adipose tissue) and colorectal adenoma risk which 105 
suggests that fat accumulation around, and within, the visceral organs may mediate 106 
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the observed positive associations between BMI and waist circumference (WC) with 107 
both adenomas and bowel cancer [6, 7]. It appears that greater body fatness at any 108 
stage in the adult life-course is a CRC risk factor. For example, among Swedish 109 
conscripts to military service, higher BMI at ages 16 – 20 years was associated with 110 
significantly greater CRC risk 35 years later [8]. Further, in a meta-analysis of seven 111 
prospective cohort studies including 18 668 men and 24 751 women (mean ages 62 112 
and 63 years, respectively), who were followed up for median 12 years, all measures 113 
of adiposity (including BMI, WC, hip circumference and waist-hip ratio) showed 114 
positive associations with colorectal cancer risk in these older adults [9]. In addition, 115 
a meta-analysis of data from prospective studies has shown that weight gain in 116 
adulthood is associated with significantly greater CRC risk in men but not in women 117 
[10]. The number of studies, especially those focussing on women, included in this 118 
review was small and the possibility of a sex-specific effect of body weight gain on 119 
CRC risk remains equivocal. Whilst the evidence for excess body weight as an 120 
aetiological factor for bowel cancer is strong, the reported effect of obesity on CRC-121 
specific survival differs between studies [11, 12] and this evidence gap should be an 122 
important focus for future research. 123 
 124 
2.1 Mechanisms linking obesity with bowel cancer 125 
 126 
The fact that increased body fatness is a risk factor for a least 13 cancer types/ sites 127 
[13] suggests that there may be common mechanisms through which greater 128 
adiposity drives the accumulation of genomic damage, reduces the efficacy of DNA 129 
repair and/ or enhances the competitiveness of tumour cells. The International 130 
Agency for Research on Cancer (IARC) Working Group concluded that there was 131 
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strong evidence for a role of altered sex hormone metabolism and of chronic 132 
inflammation in mediating the link between obesity and cancer and that there was 133 
moderate evidence for a role of abnormalities in insulin and insulin-like growth factor 134 
(IGF) signalling [13]. In the Darwinian competition for survival and growth, the 135 
combination of systemic metabolic dysregulation, pro-inflammatory cytokines and 136 
adipokines may tip the balance in favor of reduced apoptosis and increased 137 
proliferation of cancer cells [14]. 138 
 139 
2.2 Obesity, inflammation and bowel cancer 140 
 141 
It is well established that sites of chronic inflammation within the gut are associated 142 
with greater cancer risk e.g. chronic Helicobacter pylori infection leads to gastric 143 
cancer and inflammatory bowel disease leads to CRC [15]. The tumour-promoting 144 
effects of inflammation appear to be due to the proliferation enhancing effects of 145 
inflammation-related cytokines which potentiate failure to repair completely the 146 
genomic damage resulting from inflammation-related reactive oxygen and nitrogen 147 
species (RONS) [16].  In addition, there is evidence that obesity is associated with 148 
epigenetic dysregulation and altered gene expression [17] which may contribute to 149 
the epigenetic defects seen in CRC [18]. There is growing evidence that the 150 
metabolic activities of gut microorganisms may contribute to CRC risk [19, 20] but it 151 
is unclear whether this is a direct or an indirect effect given the critical role of dietary 152 
factors in modulating the composition and activities of the gut microbiota [21]. 153 
 154 
Obesity is associated with chronic low level systemic inflammation observed e.g. as 155 
elevated concentrations C-reactive protein (CRP) and other pro-inflammatory 156 
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cytokines such as IL-1β, IL-6 and TNFɑ which are produced in greater amounts as 157 
adipocytes fill with triacylglycerols [14]. This association between increased BMI and 158 
CRP appears to be stronger in women than in men and in North 159 
Americans/Europeans than in Asians [22]. In the analysis of follow-up of adolescent 160 
Swedish military conscripts, higher erythrocyte sedimentation rate (ESR) – a non-161 
specific marker of inflammation – at baseline was associated with greater CRC risk 162 
35 years later [8]. This positive relationship remained when those young people with 163 
recorded illness at baseline were excluded from the analysis [8] which is consistent 164 
with the hypothesis that chronic inflammation drives colorectal tumorigenesis. 165 
 166 
3. Aspirin and bowel cancer risk 167 
 168 
Acetylsalicylic acid (aspirin) is a non-steroidal anti-inflammatory drug (NSAID) that is 169 
used to manage a wide range of conditions including pain, fever and inflammatory 170 
diseases. In addition, aspirin is effective in reducing risk of cardiovascular disease 171 
(CVD). Using data from two large UK-based randomised trials which tested the 172 
effects of aspirin on CVD endpoints and which had reliable post-trial follow-up for 173 
more than 20 years, Flossman and colleagues observed that consumption of ≥300 174 
mg aspirin daily for ≈ 5 years is effective in primary prevention of CRC and that this 175 
effect becomes evident after about 10 years [23]. This finding was consistent with 176 
meta-analysis of data from 19 case-control studies and 11 cohort studies which 177 
showed that regular use of aspirin, or other NSAIDs, was associated consistently 178 
with lower CRC risk, especially after use for ≥10 years [23]. This supports the idea 179 
that suppressing systemic inflammation reduces CRC risk. 180 
 181 
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 182 
In the CAPP2 Study, we recruited more than 1000 individuals with Lynch Syndrome 183 
and randomised them to aspirin (600mg/d) and/or to resistant starch (30g/d) for 2+ 184 
years and determined effects on colorectal neoplasia [24]. At the end of the 185 
intervention period there was no effect of either intervention agent on colorectal 186 
neoplasia [24]. However, in anticipation that the anti-cancer effects of aspirin might 187 
take more time to become evident [23], we consented the CAPP2 Study participants 188 
to longer-term follow-up. After mean follow-up of 55.7 months, we observed that 189 
those randomised to aspirin, especially if they had taken the NSAID for at least 2 190 
years, had significantly lower incidence of CRC and of other Lynch Syndrome-191 
related cancers [25]. The relative risk of CRC was reduced by about 50% in those 192 
who had taken the anti-inflammatory agent for ≥ 2 years [25]. In addition to the likely 193 
reduction in genomic damage following suppression of inflammation by aspirin [16], 194 
there is evidence that aspirin may have particular beneficial effects in those with 195 
DNA mismatch repair defects by “selecting” for stem cells that show greater 196 
microsatellite stability [26]. 197 
 198 
Given the role of obesity in enhancing CRC risk in the general population, we 199 
hypothesised that obesity would influence bowel cancer risk in those with the cancer 200 
predisposition Lynch Syndrome. Using data from the CAPP2 Study, we observed 201 
that CRC risk was significantly greater in obese Lynch Syndrome patients [27]. For 202 
reasons that are not yet evident, the excess CRC risk associated with obesity 203 
appeared to be restricted to those participants with mutations in MLH1 [27]. 204 
However, this greater CRC risk associated with obesity was abrogated when the 205 
Lynch Syndrome patients were randomised to aspirin [27]. These observations 206 
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support the hypothesis that obesity drives CRC development, even in those at high 207 
genetic risk of the disease, and that inflammation may be one of the damaging 208 
processes contributing to carcinogenesis.  209 
 210 
4. Weight loss and colorectal cancer risk 211 
 212 
When compared with the wealth of evidence demonstrating links between 213 
overweight or obesity and risk of a wide range of common non-communicable 214 
diseases [28], there is limited information about the effects of weight loss in the 215 
obese on incidence of, or mortality from, obesity-related diseases. A recent 216 
systematic review and meta-analysis of data from 54 RCTs of lifestyle-based weight 217 
loss interventions reported significantly lower all-cause mortality over a median trial 218 
duration of two years [29]. There were no detectable effects on specific causes of 219 
mortality including cardiovascular disease and cancer [29].  220 
 221 
In contrast with behavioural interventions, bariatric (obesity) surgery produces much 222 
bigger and more sustained losses of body weight and substantial improvements in 223 
many health outcomes including lower risk of cancer after 10 years of follow-up [30, 224 
31]. However, the effects of bariatric surgery on bowel cancer risk remain unclear 225 
and, because of the changes in gut physiology resulting from such surgery, it should 226 
not be assumed that any benefits for cancer overall will also apply to CRC. For 227 
example, a Swedish observational study reported apparently greater CRC risk after 228 
bariatric surgery [32] whereas a recent retrospective cohort study of patients 229 
undergoing bariatric surgery in the USA reported lower colon cancer (P = 0.04) at 230 
mean 3.5 years follow up [31]. To address this issue, we undertook a systematic 231 
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review and meta-analysis in which we found 4 studies which met our inclusion 232 
criteria and that showed, on average, 27% lower CRC risk in obese individuals who 233 
had undergone bariatric surgery [33]. Very recently, Aravani and colleagues used 234 
data from a cohort of >1 million obese individuals in England to investigate links 235 
between bariatric surgery and CRC risk [34]. Almost 40,000 of these initially obese 236 
individuals underwent bariatric surgery among whom there were 43 CRC cases in 237 
the period of follow-up and no effect on CRC incidence was detected [34]. Overall, 238 
current evidence suggests that commonly-used types of bariatric surgery do not 239 
increase CRC risk and, indeed, may decrease risk. However, given the relatively 240 
small number of studies and the small number of CRC patients investigated, this 241 
conclusion is tentative. 242 
 243 
4.1 Mechanisms through which weight loss in obese individuals may reduce CRC 244 
risk 245 
 246 
In an attempt to understand how weight loss in obese people may alter bowel cancer 247 
risk, Steinbach et al. (1994) enrolled 8 obese patients in a behaviour modification 248 
weight-reduction programme [35]. The primary outcome measure was the number 249 
and distribution of dividing cells in crypts obtained from colorectal mucosal biopsies 250 
(36, 37, 38]. After 12 weeks of dietary energy restriction, the participants had lost on 251 
average 8.6% body weight and showed a 39% reduction in whole-crypt labelling 252 
index (P < 0.001) and a 57% reduction in upper crypt labelling index (P < 0.05) [35].  253 
This reduction in the total number of dividing cells within the crypt and a reduction in 254 
mitotic cells in the upper part of the crypt is consistent with the hypothesis that the 255 
weight reduction intervention lowered bowel cancer risk. Similarly, Pendyala et al. 256 
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(2011) investigated effects of behaviour-induced weight loss on mucosal 257 
inflammation markers in 10 healthy, pre-menopausal women. After the intervention, 258 
the women had lost 10.1 ± 1% of their initial weight and this was accompanied by a 259 
significant reduction in several mucosal inflammatory biomarkers including TNF-α, 260 
IL-1β, IL-8, and monocyte chemotactic protein 1 concentrations [39]. In addition, data 261 
from gene expression arrays revealed dramatic down-regulation of pro-inflammatory 262 
cytokine and chemokine pathways, prostaglandin metabolism, and of proto-263 
oncogenes JUN and FOS [39]. The authors concluded that diet-induced weight loss 264 
in obese individuals reduces colorectal mucosal inflammation and modulates 265 
inflammatory and cancer-related pathways [39]. 266 
 267 
In contrast with the (albeit limited) evidence of likely benefit of diet-induced weight 268 
loss on biomarkers of CRC risk, evidence of the effects of the much larger amounts 269 
of weight loss induced by bariatric surgery on CRC biomarkers is more mixed. In 270 
initially morbidly obese individuals whose BMI fell by 12.6 units at 26 weeks after 271 
bariatric surgery, rates of mitosis increased whilst apoptosis decreased in colorectal 272 
mucosal crypts and there was elevated mucosal expression of pro-inflammatory 273 
genes including COX-1 and COX-2 [40]. The elevated crypt cell proliferation was 274 
sustained at 3 years after surgery [41]. However, in a further study by the same 275 
research team, weight loss following bariatric surgery had no effect on crypt cell 276 
proliferation at 6 months and circulating CRP concentration fell [41].  Kant and 277 
colleagues hypothesised that the differences between the two studies could be 278 
attributed to differences in the type of bariatric surgery used viz. Roux-en-Y gastric 279 
bypass (RYGB) in the study by Sainsbury and colleagues (2008) and sleeve 280 
gastrectomy in the study by Kant et al. (2014) [42]. More recently, we have reported 281 
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changes in inflammatory and other CRC biomarkers before, and 6.5 months after, 282 
RYBG surgery in initially obese individuals [43].  Following surgery, participants lost 283 
on average 28.5 kg body mass and showed improvements in systemic markers of 284 
inflammation (CRP) and of glycaemic control (fasting glucose, HbA1c, insulin and 285 
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)) [43]. In addition, 286 
at 6.5 months post-surgery, there was a significant fall in expression of the pro-287 
inflammatory gene COX-1 and reduced total mitoses and mitoses in the top half of 288 
the crypt in the colorectal mucosa [43]. These findings are consistent with the 289 
hypothesis that weight loss induced by bariatric surgery can lower CRC risk [33].   290 
 291 
5. Future research 292 
A recent systematic review reported very low quality evidence for an effect of weight 293 
loss interventions on cancer mortality (n=8 trials, 34 events; risk ratio 0.58, 95% 294 
confidence interval 0.30 to 1.11 [44]. Given the paucity of available evidence, further 295 
research on the effects of weight loss in obese individuals on future CRC risk is 296 
warranted.  Weight loss could be induced by lifestyle changes (reduced dietary 297 
energy intake and/or increased energy expenditure in physical activity), use of 298 
pharmaceutical agents or bariatric surgery [45] but lifestyle-based interventions are 299 
likely to minimise adverse effects. Given the evidence that certain nutritional risk 300 
factors including alcoholic beverages, red or processed meat, and 301 
overweight/obesity increase CRC risk in those with a family history of the disease 302 
[46], it will be especially important to investigate such factors in those with LS and in 303 
others at higher CRC risk for familial reasons. A feasibility study by Anderson and 304 
colleagues suggests that lifestyle-based interventions may be feasible and 305 
acceptable in those with a family history of CRC such as LS patients [47]. The 306 
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evidence that aspirin reduces CRC risk suggests that inflammation may be an 307 
important driver of the genomic damage that is responsible for the development of 308 
bowel cancer but this putative mechanism needs further investigation. In addition, a 309 
recent meta-analysis of data from primary prevention trials testing efficacy of aspirin 310 
suggests that there may be significant interactions between aspirin dose and body 311 
mass on both cardiovascular and cancer outcomes [48]. This analysis showed that 312 
low-dose aspirin (75-100mg/d) reduced CRC risk in participants whose body mass 313 
was <70kg but not in those weighing ≥70kg. In addition, higher aspirin doses (≥ 314 
325mg/d) reduced CRC risk in those weighing up to 80kg [48]. These findings 315 
highlight evidence gaps in respect of effective (and safe) doses of aspirin for CRC 316 
prevention in obese individuals. 317 
 318 
6. Conclusions 319 
 320 
There is now convincing evidence that excess adiposity is associated with increased 321 
bowel cancer risk and that the increased risk is apparent even among those with 322 
Lynch Syndrome who are genetically predisposed to the disease. It seems likely that 323 
genomic damage resulting from obesity-related inflammation is a key driver of 324 
colorectal tumorigenesis but mechanisms may also include altered insulin/ IGF1 325 
signalling which may give tumour cells a competitive advantage. The importance of 326 
inflammation as a mediator of the effects of obesity is supported by the fall in CRC 327 
risk which follows sustained exposure to NSAIDs such as aspirin and the abrogation 328 
of the excess CRC risk in obese patients with Lynch Syndrome who were 329 
randomised to aspirin. Since the available evidence about the effects of weight loss 330 
in the obese on CRC risk is limited, this should be a high priority for future research. 331 
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In the meantime, to lower the global CRC burden, it would be prudent to institute 332 
effective public measures to reduce the development of obesity and to enable those 333 
who are obese to lose weight. Such interventions are likely to benefit all sections of 334 
the population including those at higher risk due to familial conditions such as Lynch 335 
Syndrome. 336 
 337 
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